Kim DH - Search Results

1

BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.

Moon JH, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, Kim DH. Moon JH, et al. Among authors: kim dh, kim k. Leuk Res. 2010 Feb;34(2):166-72. doi: 10.1016/j.leukres.2009.05.009. Epub 2009 Jun 10. Leuk Res. 2010. PMID: 19520430

2

Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation.

Kim DH, Sohn SK, Kim JG, Lee NY, Sung WJ, Baek JH, Suh JS, Lee KS, Lee KB. Kim DH, et al. Among authors: kim jg. Ann Hematol. 2005 Jan;84(1):25-32. doi: 10.1007/s00277-004-0942-z. Epub 2004 Sep 3. Ann Hematol. 2005. PMID: 15349754

3

Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia.

Kim DH, Lee NY, Kim JG, Sohn SK, Won DI, Suh JS, Lee GS, Chae SC, Lee KB. Kim DH, et al. Among authors: kim jg. Leuk Lymphoma. 2005 Jan;46(1):63-70. doi: 10.1080/10428190400010759. Leuk Lymphoma. 2005. PMID: 15621782 Clinical Trial.

4

Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.

Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, Chae SC, Lee KS, Lee KB. Kim JG, et al. Among authors: kim dh. Leuk Lymphoma. 2005 Jun;46(6):885-91. doi: 10.1080/10428190500054491. Leuk Lymphoma. 2005. PMID: 16019534

5

Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes.

Kim DH, Lee NY, Sung WJ, Baek JH, Kim JG, Sohn SK, Suh JS, Lee KS, Lee KB. Kim DH, et al. Among authors: kim jg. Acta Haematol. 2005;114(2):78-83. doi: 10.1159/000086579. Acta Haematol. 2005. PMID: 16103629

6

Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.

Sung WJ, Kim DH, Sohn SK, Kim JG, Baek JH, Jeon SB, Moon JH, Ahn BM, Lee KB. Sung WJ, et al. Among authors: kim dh, kim jg. Jpn J Clin Oncol. 2005 Oct;35(10):612-6. doi: 10.1093/jjco/hyi149. Epub 2005 Sep 19. Jpn J Clin Oncol. 2005. PMID: 16172175 Clinical Trial.

7

Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia.

Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, Kim JG, Suh JS, Do YR, Lee KB. Kim DH, et al. Among authors: kim jg. Int J Cancer. 2006 May 1;118(9):2195-201. doi: 10.1002/ijc.21666. Int J Cancer. 2006. PMID: 16331627

8

Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia.

Kim DH, Lee NY, Baek JH, Kim JG, Sohn SK, Suh JS, Lee KS, Lee KB. Kim DH, et al. Among authors: kim jg. Leuk Lymphoma. 2006 Mar;47(3):461-7. doi: 10.1080/10428190500331626. Leuk Lymphoma. 2006. PMID: 16396769 Clinical Trial.

9

Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.

Baek JH, Sohn SK, Kim DH, Kim JG, Yang DH, Kim YK, Lee JJ, Kim HJ. Baek JH, et al. Among authors: kim yk, kim hj, kim dh, kim jg. Acta Haematol. 2007;117(2):109-14. doi: 10.1159/000097386. Epub 2006 Nov 28. Acta Haematol. 2007. PMID: 17135724 Clinical Trial.

10

Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients.

Kim DH, Lee NY, Lee MH, Sohn SK, Do YR, Park JY. Kim DH, et al. Br J Haematol. 2008 Jan;140(1):71-9. doi: 10.1111/j.1365-2141.2007.06887.x. Epub 2007 Nov 3. Br J Haematol. 2008. PMID: 17983459 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,081 results

Search Page

Filters